Brain biometals and Alzheimer's disease–boon or bane?

International Journal of Neuroscience

Volumn 127, Issue 2, 2017, Pages 99-108

  Prakash, Atish ^a,b   Dhaliwal, Gagandeep Kaur ^b   Kumar, Puneet ^b   Majeed, Abu Bakar Abdul ^a  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b ISF COLLEGE OF PHARMACY   (India)

Author keywords

Alzheimer's disease; amyloid ; metal neurotoxicity; oxidative stress

Indexed keywords

ALUMINUM; COPPER; IRON; MAGNESIUM; MANGANESE; METAL; ZINC; TRACE ELEMENT;

ALZHEIMER DISEASE; BRAIN LEVEL; HUMAN; METAL METABOLISM; NEUROPATHOLOGY; PATHOPHYSIOLOGY; REVIEW; BRAIN; HOMEOSTASIS; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY;

ALZHEIMER DISEASE; BRAIN; HOMEOSTASIS; HUMANS; OXIDATIVE STRESS; TRACE ELEMENTS;

EID: 84966615005     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207454.2016.1174118     Document Type: Review

References (97)

1. Palop JJ, Mucke L. Amyloid-[beta]-induced neuronal dysfunction in Alzheimer's disease:from synapses toward neural networks. Nat Neurosci 2010;13:812–8.
2. Jonsson T, Atwal JK, Steinberg S, et al. A mutation in APP protects against Alzheimer's disease and age-related cognitive decline. Nature 2012;488:96–9.
3. Harold D, Abraham R, Hollingworth P, et al. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 2009;41:1088–93.
4. Ray S, Britschgi M, Herbert C, et al. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat Med 2007;13:1359–62.
5. Arendt T., Synaptic degeneration in Alzheimer's disease. Acta Neuropathol 2009;118:167–79.
6. Leduc V, Domenger D, De Beaumont L, et al. Function and comorbidities of apolipoprotein e in Alzheimer's disease. Int J Alzheimers Dis 2011;2011:974361.
7. Al Harthi F, Huraib GB, Zouman A, et al. Apolipoprotein E gene polymorphism and serum lipid profile in Saudi patients with psoriasis. Dis Markers 2014;2014:239645.
8. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012;148:1204–22.
9. Su B, Wang X, Nunomura A, et al. Oxidative stress signaling in Alzheimers disease. Curr Alzheimer Res 2008;5:525–32.
10. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron 2010;66:631–45.
11. Roberts BR, Ryan TM, Bush AI, et al. The role of metallobiology and amyloid‐β peptides in Alzheimer's disease. J Neurochem 2012;120:149–66.
12. Jomova K, Vondrakova D, Lawson M, et al. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem 2010;345:91–104.
13. Breydo L, Uversky VN. Role of metal ions in aggregation of intrinsically disordered proteins in neurodegenerative diseases. Metallomics 2011;3:1163–80.
14. Oshima E, Ishihara T, Yokota O, et al. Accelerated tau aggregation, apoptosis and neurological dysfunction caused by chronic oral administration of aluminum in a mouse model of tauopathies. Brain Pathol 2013;23:633–44.
15. Buraimoh AA, Ojo SA, Hambolu JO, et al. Histological study of the effects of aluminium chloride exposure on the testis of Wistar rats. Am Int J Contemp Res 2012;2:114–22.
16. Klatzo I. Neuropathological aspects of brain edema. J Neuropathol Exp Neurol 1967;26:1–14.
17. Crapper D, Quittkat S, Krishnan S, et al. Intranuclear aluminum content in Alzheimer's disease, dialysis encephalopathy, and experimental aluminum encephalopathy. Acta Neuropathol 1980;50:19–24.
18. Exley C., Aluminium and iron, but neither copper nor zinc, are key to the precipitation of β-sheets of Aβ 42 in senile plaque cores in Alzheimer's disease. J Alzheimers Dis 2006;10:173–7.
19. House E, Collingwood J, Khan A, et al. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer's disease. J Alzheimers Dis. 2004;6:291–301.
20. Exley C, Esiri M. Severe cerebral congophilic angiopathy coincident with increased brain aluminium in a resident of Camelford, Cornwall, UK. J Neurol Neurosurg Psychiatry 2006;77:877–9.
21. Kawahara M, Kato-Negishi M. Link between aluminum and the pathogenesis of Alzheimer's disease:the integration of the aluminum and amyloid cascade hypotheses. Int J Alzheimers Dis 2011;2011:276393.
22. Wu Z, Du Y, Xue H, et al. Aluminum induces neurodegeneration and its toxicity arises from increased iron accumulation and reactive oxygen species (ROS) production. Neurobiol Aging 2012;33:199/e1–12.
23. De Sole P, Rossi C, Chiarpotto M, et al. Possible relationship between Al/ferritin complex and Alzheimer's disease. Clin Biochem 2013;46:89–93.
24. Moore PB, Day JP, Taylor GA, et al. Absorption of aluminium-26 in Alzheimer's disease, measured using accelerator mass spectrometry. Dement Geriatr Cogn Disord 2000;11:66–9.
25. Campbell A, Becaria A, Lahiri D, et al. Chronic exposure to aluminum in drinking water increases inflammatory parameters selectively in the brain. J Neurosci Res 2004;75:565–72.
26. Drago D, Cavaliere A, Mascetra N, et al. Aluminum modulates effects of β amyloid1-42 on neuronal calcium homeostasis and mitochondria functioning and is altered in a triple transgenic mouse model of Alzheimer's disease. Rejuvenation Res 2008;11:861–71.
27. Exley C., The aluminium-amyloid cascade hypothesis and Alzheimer's disease. Subcell Biochem 2005;38:225–34.
28. Rondeau V, Jacqmin-Gadda H, Commenges D, et al. Aluminum and silica in drinking water and the risk of Alzheimer's disease or cognitive decline:findings from 15-year follow-up of the PAQUID cohort. Am J Epidemiol 2009;169:489–96.
29. Chasapis CT, Loutsidou AC, Spiliopoulou CA, et al. Zinc and human health:an update. Arch Toxicol 2012;86:521–34.
30. Sensi SL, Paoletti P, Bush AI, et al. Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 2009;10:780–91.
31. Frederickson CJ, Koh J-Y, Bush AI. The neurobiology of zinc in health and disease. Nat Rev Neurosci 2005;6:449–62.
32. Frazzini V, Rockabrand E, Mocchegiani E, Sensi S. Oxidative stress and brain aging:is zinc the link? Biogerontology 2006;7:307–14.
33. Huang L, Tepaamorndech S. The SLC30 family of zinc transporters–a review of current understanding of their biological and pathophysiological roles. Mol Aspects Med 2013;34:548–60.
34. Takeda A, Tamano H. Insight into zinc signaling from dietary zinc deficiency. Brain Res Rev 2009;62:33–44.
35. Viles JH., Metal ions and amyloid fiber formation in neurodegenerative diseases. Copper, zinc and iron in Alzheimer's, Parkinson's and prion diseases. Coord Chem Rev 2012;256:2271–84.
36. Kim I, Park EJ, Seo J, et al. Zinc stimulates tau S214 phosphorylation by the activation of Raf/mitogen-activated protein kinase-kinase/extracellular signal-regulated kinase pathway. Neuroreport 2011;22:839–44.
37. Kozin S, Cheglakov I, Ovsepyan A, et al. Peripherally applied synthetic peptide isoAsp7-Aβ (1-42) triggers cerebral β-amyloidosis. Neurotox Res 2013;24:370–6.
38. Adlard PA, Parncutt JM, Finkelstein DI, Bush AI. Cognitive loss in zinc transporter-3 knock-out mice:a phenocopy for the synaptic and memory deficits of Alzheimer's disease? J Neurosci 2010;30:1631–6.
39. Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with Alzheimer apeptides:identification of an attomolar affinity copper binding site on A1-42. J Neurochem 2000;75:1219–33.
40. Lovell M, Robertson J, Teesdale W, et al. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 1998;158:47–52.
41. Davies B, Sehring SA, Partridge JC, et al. Barriers to palliative care for children:perceptions of pediatric health care providers. Pediatrics 2008;121:282–8.
42. Scheiber IF, Dringen R. Astrocyte functions in the copper homeostasis of the brain. Neurochem Int 2013;62:556–65.
43. Hopt A, Korte S, Fink H, et al. Methods for studying synaptosomal copper release. J Neurosci Methods 2003;128:159–72.
44. Scheiber IF, Schmidt MM, Dringen R. Zinc prevents the copper-induced damage of cultured astrocytes. Neurochem Int 2010;57:314–22.
45. Liang Q, Zhou B. Copper and manganese induce yeast apoptosis via different pathways. Mol Biol Cell 2007;18:4741–9.
46. Hung YH, Bush AI, Cherny RA. Copper in the brain and Alzheimer's disease. J Biol Inorg Chem 2010;15:61–76.
47. Huang Y, Mucke L. Alzheimer mechanisms and therapeutic strategies. Cell 2012;148:1204–22.
48. Camponeschi F, Valensin D, Tessari I, et al. Copper (I)-α-synuclein interaction:structural description of two independent and competing metal binding sites. Inorg Chem 2013;52:1358–67.
49. Qiu J, Ning P, Wang X, et al. Removing carbonyl sulfide with metal-modified activated carbon. Frontiers Environ Sci Eng 2014;10:11–8.
50. Nagarajan R, Jonathan M, Roy PD, et al. Metal concentrations in sediments from tourist beaches of Miri City, Sarawak, Malaysia (Borneo Island). Mar Pollut Bull 2013;73:369–73.
51. Bucossi S, Ventriglia M, Panetta V, et al. Copper in Alzheimer's disease:a meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 2011;24:175–85.
52. Martinez-Finley EJ, Gavin CE, Aschner M, et al. Manganese neurotoxicity and the role of reactive oxygen species. Free Radic Biol Med 2013;62:65–75.
53. Cordova FM, Aguiar Jr AS, Peres TV, et al. In vivo manganese exposure modulates Erk, Akt and Darpp-32 in the striatum of developing rats, and impairs their motor function. PLOS One 2012;7:e33057.
54. Guilarte TR., APLP1, Alzheimer's-like pathology and neurodegeneration in the frontal cortex of manganese-exposed non-human primates. Neurotoxicology 2010;31:572–4.
55. Aschner M, Guilarte TR, Schneider JS, Zheng W. Manganese:recent advances in understanding its transport and neurotoxicity. Toxicol Appl Pharmacol 2007;221:131–47.
56. Mattson MP., Calcium and neurodegeneration. Aging Cell 2007;6:337–50.
57. Dydak U, Jiang Y-M, Long L-L, et al. In vivo measurement of brain GABA concentrations by magnetic resonance spectroscopy in smelters occupationally exposed to manganese. Environ Health Perspect 2011;119:219–24.
58. Gunter TE, Gavin CE, Aschner M, Gunter KK. Speciation of manganese in cells and mitochondria:a search for the proximal cause of manganese neurotoxicity. Neurotoxicology 2006;27:765–76.
59. Hamai D, Bondy SC. Oxidative basis of manganese neurotoxicity. Ann New York Acad Sci 2004;1012:129–41.
60. Sidoryk‐Węgrzynowicz M, Lee E, Albrecht J, Aschner M. Manganese disrupts astrocyte glutamine transporter expression and function. J Neurochem 2009;110:822–30.
61. Park RM, Bouchard MF, Baldwin M, et al. Respiratory manganese particle size, time-course and neurobehavioral outcomes in workers at a manganese alloy production plant. Neurotoxicology 2014;45:276–84.
62. Kim Y, Bowler RM, Abdelouahab N, et al. Motor function in adults of an Ohio community with environmental manganese exposure. Neurotoxicology 2011;32:606–14.
63. Kim T, Momin E, Choi J, et al. Mesoporous silica-coated hollow manganese oxide nanoparticles as positive T 1 contrast agents for labeling and MRI tracking of adipose-derived mesenchymal stem cells. J Am Chem Soc 2011;133:2955–61.
64. Moos T, Morgan EH. The metabolism of neuronal iron and its pathogenic role in neurological disease:review. Ann New York Acad Sci 2004;1012:14–26.
65. Mu C, Walsby CJ. Ruthenium anticancer compounds with biologically‐derived ligands. In:Ligand design in medicinal inorganic chemistry. Chichester:John Wiley & Sons, Ltd; 2014. DOI:10.1002/9781118697191.ch15
66. Gregory A, Polster BJ, Hayflick SJ. Clinical and genetic delineation of neurodegeneration with brain iron accumulation. J Med Genet 2009;46:73–80.
67. Volpe SL., Magnesium in disease prevention and overall health. Adv Nutr 2013;4:378S–83S.
68. Abumaria N, Yin B, Zhang L, et al. Effects of elevation of brain magnesium on fear conditioning, fear extinction, and synaptic plasticity in the infralimbic prefrontal cortex and lateral amygdala. J Neurosci 2011;31:14871–81.
69. Slutsky I, Abumaria N, Wu L-J, et al. Enhancement of learning and memory by elevating brain magnesium. Neuron 2010;65:165–77.
70. Selkoe DJ., Soluble oligomers of the amyloid β-protein impair synaptic plasticity and behavior. Behav Brain Res 2008;192:106–13.
71. Maggio M, Ceda G, Lauretani F, et al. Magnesium and anabolic hormones in older men. Int J Androl 2011;34:e594–e600.
72. Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med 2008;359:895–905.
73. Xu H, Finkelstein DI, Adlard PA. Interactions of metals and apolipoprotein E in Alzheimer's disease. Front Aging Neurosci 2014;12:1–7.
74. Lee J, Y Cho E, Kim TY, et al. Apolipoprotein E ablation decreases synaptic vesicular zinc in the brain. Biometals 2010;23:1085–95
75. Adlard PA, Bush AI. Metals and Alzheimer's disease. J Alzheimers Dis 2006;10:145–63
76. Takeda A., Essential trace metals and brain function. Yakugaku Zasshi 2004;124:577–85.
77. Oteiza PI, Olin KL, Fraga CG, et al. Zinc deficiency causes oxidative damage to proteins, lipids and DNA in rat testes. J Nutr 1995;125:823–9.
78. Hozumi I., Roles and therapeutic potential of metallothioneins in neurodegenerative diseases. Curr Pharm Biotechnol 2013;14:408–13.
79. Scheiber IF, Mercer JF, Dringen R. Metabolism and functions of copper in brain. Prog Neurobiol 2014;116:33–57.
80. Purchase R., The link between copper and Wilson's disease. Sci Prog 2013;96:213–23.
81. Culotta VC, Yang M, O'Halloran TV. Activation of superoxide dismutases:putting the metal to the pedal. Biochim Biophys Acta 2006;1763:747–58.
82. Fukai T, Ushio-Fukai M. Superoxide dismutases:role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 2011;15:1583–606.
83. Wrigglesworth JM, Baum H. Iron-dependent enzymes in the brain. New York:Taylor and Francis; 1988.
84. Schipper HM., Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim Biophys Acta 2012;1822:350–60.
85. Simpson IA, Ponnuru P, Klinger ME, et al. A novel model for brain iron uptake:introducing the concept of regulation. J Cereb Blood Flow Metab 2015;35:48–57.
86. Zechel S, Huber-Wittmer K, von Bohlen und Halbach O. Distribution of the iron-regulating protein hepcidin in the murine central nervous system. J Neurosci Res 2006;84:790–800.
87. Beard JL., Iron biology in immune function, muscle metabolism and neuronal functioning. J Nutr 2001;131:568S–79S.
88. Miyata M, Smith JD. Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and beta-amyloid peptides. Nat Genet 1996;14:55–61.
89. Valentine JS, Doucette PA, Zittin Potter S. Copper-zinc superoxide dismutase and amyotrophic lateral sclerosis. Annu Rev Biochem 2005;74:563–93.
90. Drago D, Bolognin S, Zatta P. Role of metal ions in the abeta oligomerization in Alzheimer's disease and in other neurological disorders. Curr Alzheimer Res 2008;5:500–7.
91. Zawilla NH, Taha FM, Kishk NA, et al. Occupational exposure to aluminum and its amyloidogenic link with cognitive functions. J Inorg Biochem 2014;139:57–64.
92. Zhang QL, Jia L, Jiao X, et al. APP/PS1 transgenic mice treated with aluminum:an update of Alzheimer's disease model. Int J Immunopathol Pharmacol 2012;25:49–58.
93. Duce JA, Bush AI. Biological metals and Alzheimer's disease:implications for therapeutics and diagnostics. Prog Neurobiol 2010;92:1–18.
94. Tuschl K, Mills PB, Clayton PT. Manganese and the brain. Int Rev Neurobiol 2013;110:277–312.
95. Sen A, Nelson TJ, Alkon DL. ApoE4 and Aβ Oligomers reduce BDNF expression via HDAC nuclear translocation. J Neurosci 2015;35:7538–51.
96. Xu H, Gupta VB, Martins IJ, et al. Zinc affects the proteolytic stability of apolipoprotein E in an isoform-dependent way. Neurobiol Dis 2015;81:38–48.
97. Zappasodi F, Salustri C, Babiloni C, et al. An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 2008;1215:183–9.